NVTIA Rice Bran Fatty Alcohol-Plant Sterol Complex for Cardiovascular and Cerebrovascular Protection: Preclinical Efficacy Benchmarks and a Randomized Clinical Trial Protocol

Abstract

Background: Dyslipidemia, endothelial injury, oxidative stress, and impaired microcirculation are mechanistically linked to cardiovascular and cerebrovascular risk. We developed an NVTIA branded raw-material complex built around rice bran fatty alcohol and plant sterol, with earthworm protein, bitter melon peptide, antioxidant components, lipid-lowering components, vascular maintenance agents, and excipients.

Objective: We evaluated the preclinical efficacy pattern of the NVTIA complex against model control and comparator formulations, and we designed a publishable randomized clinical evaluation framework for subsequent human confirmation. Methods: We summarized a controlled preclinical efficacy benchmark using lipid indices (TC, TG, LDL-C, HDL-C), vascular endothelial growth factor (VEGF), and superoxide dismutase (SOD). We then compared the biological direction of the NVTIA formulation with established clinical evidence on plant sterols/stanols, rice-bran lipid fractions, and antioxidant vascular-support ingredients. A prospective 12-week double-blind randomized clinical protocol is proposed for implementation in a cardiology clinical-trials setting. Results: In the optimized NVTIA benchmark group, TC, TG, and LDL-C were reduced by 50.3%, 64.2%, and 63.0%, respectively, versus model control, while HDL-C, VEGF, and SOD increased by 86.6%, 70.1%, and 86.3%. Compared with the commercial comparator in the same model, optimized NVTIA showed lower TC, TG, and LDL-C by 32.5%, 43.0%, and 44.1%, respectively, and higher HDL-C, VEGF, and SOD by 33.0%, 29.9%, and 32.4%. Published human evidence supports LDL-C lowering by plant sterols/stanols and lipid improvement by rice-bran oil; however, a human trial is still required to confirm the full NVTIA complex as a combined branded raw material. Conclusion: The NVTIA complex demonstrates a coherent preclinical profile across lipid regulation, vascular repair, and antioxidant protection. We propose a randomized clinical trial to determine whether the multi-component raw-material system can achieve clinically meaningful effects beyond single-ingredient comparators.